Abstract
We thank Dr Riquet and colleagues [1Riquet M. Arame A. Foucault C. Does presence of hematologic malignancy change our approach to non-small cell lung cancer? (letter).Ann Thorac Surg. 2011; 91: 1652-1653Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar] for their comments on our study [2Kim M.P. Correa A.M. Swisher S.G. et al.Non-small cell lung cancer resection in lymphoma patients.Ann Thorac Surg. 2010; 90: 210-216Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar] that looked at surgical results for lymphoma patients who underwent resection for non-small cell lung cancer. Dr Riquet and colleagues [1Riquet M. Arame A. Foucault C. Does presence of hematologic malignancy change our approach to non-small cell lung cancer? (letter).Ann Thorac Surg. 2011; 91: 1652-1653Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar] have strengthened our conclusions by providing their experience with patients with lymphoma who underwent resection for non-small cell lung cancer. They found that there has been higher incidence of patients with lymphoma with lung cancer in recent periods likely because the treatment of lymphoma has been very effective and this group has improved survival from that disease. In addition, their patients who had lymphoma and lung resection for non-small cell lung cancer had a 5-year survival of 38%, and there was no difference in survival in synchronous or metachronous malignancy and lung cancer. Our study [2Kim M.P. Correa A.M. Swisher S.G. et al.Non-small cell lung cancer resection in lymphoma patients.Ann Thorac Surg. 2010; 90: 210-216Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar] found that patients with active lymphoma or a history of lymphoma were not at an elevated risk of morbidity or perioperative mortality after lung cancer resection. However, the 5-year overall survival rate among lymphoma patients who underwent lung cancer resection was significantly lower without a difference in lung cancer-specific survival. This is probably because patients with lymphoma and lung cancer are at risk of dying from recurrent lung cancer as well as recurrent lymphoma or secondary hematologic malignancy. We concur with Dr Riquet and colleagues that the presence of active lymphoma or a history of treated lymphoma should not be a contraindication to the surgical treatment of patients with lung cancer. Does Presence of Hematologic Malignancy Change our Approach to Non-Small Cell Lung Cancer?The Annals of Thoracic SurgeryVol. 91Issue 5PreviewWe read the article of Kim and colleagues [1] with interest. The article reports the results of surgical resection for non-small cell lung cancer (NSCLC) in patients with lymphoma (synchronous or metachronous). First, among the 4,796 patients who had surgical lung resection in our service for NSCLC between 1983 and 2007, there were 796 patients (17.95%) who had a history of another cancer and 65 patients (1.36%) with multiple cancers. Lymphoma was present in 36 patients (0.75%) (6 Hodgkin's disease and 30 non-Hodgkin's lymphoma), which shows the rarity of this association. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
